Testicular seminoma

Summary

Testicular seminoma (MONDO:0003669) is a disease and 6 clinical trials. Top therapeutic interventions include imatinib and sodium thiosulfate. A subtype of testicular pure germ cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
• Clinical trials: 6

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 100 000	1.71	Europe	Validated
Lifetime Prevalence	1-5 / 10 000	46.01	Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	testicular seminoma
Mondo ID	MONDO:0003669
EFO	EFO:0003101
Orphanet	842
DOID	DOID:5842
NCIT	C7328
SNOMED CT	255107005
UMLS	C5551428
MedGen	1790467
GARD	0004792
Anatomy (UBERON)	UBERON:0000473
Is cancer (heuristic)	no

Also known as: seminoma of testis · seminoma of the testis · seminomatous germ cell tumor of testis · seminomatous germ cell tumour of testis · testicular seminoma · testicular seminoma (disease) · testicular seminoma Pure · testicular seminomatous germ cell tumor · testicular seminomatous germ cell tumour · testis seminoma

Data availability: 1 HPO phenotype · 5 cell lines.

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › gonadal germ cell tumor › testicular germ cell tumor › testicular pure germ cell tumor › testicular seminoma

Related subtypes (3): testicular trophoblastic tumor, testicular yolk sac tumor, testicular embryonal carcinoma

Subtypes (4): tubular variant testicular seminoma, cribriform variant testicular seminoma, pseudoglandular variant testicular seminoma, spermatocytic seminoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05500391	PHASE2	RECRUITING	Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
NCT00042952	PHASE2	TERMINATED	Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
NCT07218913	PHASE1	RECRUITING	Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
NCT02537548	Not specified	ACTIVE_NOT_RECRUITING	Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
NCT05345158	Not specified	RECRUITING	R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma
NCT01434355	Not specified	COMPLETED	DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IMATINIB	4	1
SODIUM THIOSULFATE	4	1